Where can I find the primary clinical evidence?

Primary trials are published in peer-reviewed journals (NEJM, JAMA, Lancet) with PubMed PMIDs cited throughout GLP1 One Rx.

SELECT Trial Results — Cardiovascular Outcomes

SELECT Trial Results

Updated October 16, 2026 with prices and facts re-checked October 14, 2026.

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

Clinical referencePubMed-linkedUpdated October 16, 2026

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026

Overview

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

PubMed citations

PMID 37952131

Related clinical pages

Questions readers ask

Who was enrolled in the SELECT trial?

SELECT enrolled adults without diabetes who had overweight or obesity and established cardiovascular disease. It was published in NEJM in 2023 (PMID 37952131) and tested semaglutide 2.4 mg weekly.

How much did semaglutide cut heart attack and stroke risk in SELECT?

Semaglutide 2.4 mg weekly produced a 20% reduction in major adverse cardiovascular events (MACE) over a median of 39.8 months in adults with overweight or obesity and established cardiovascular disease.

What changed for Wegovy because of SELECT?

SELECT results led to Wegovy’s 2024 FDA expansion to include cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease, in addition to chronic weight management.